Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

Researchers leading the SWOG S1712 clinical trial have found that adding ... deep enough to warrant discontinuing treatment. A new preclinical model using CRISPR, an advanced technology that ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the ...

Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...

A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

"We are thrilled with the positive outcomes from our preclinical studies," Biolexis ... the biotech plans to conduct IND-enabling studies and begin human clinical trials early next year, chief ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Kineta will be trading under the symbol “KANT” on OTC PinkKineta will continue to pursue strategic alternatives as previously announcedTuHURA ...